The Quantellect read.As of Nov 19, 2026, 17 active firms cover Ascendis Pharma AS: 17 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $269.00 to $355.00, so the covering firms are broadly aligned. The average target of $315.35 sits 17% above the current $270.19. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 88% this year and 45% next, consensus EPS building from about $1.52 next quarter toward $10.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 active firms
Buy
Strong Buy00%
Buy17100%
Neutral00%
Sell00%
Strong Sell00%
Based on 17 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$315.35
+16.7% upside
Average target across 17 active firms as of Nov 19, 2026 vs $270.19 current
Highest Target$355.00
Average Target$315.35
Lowest Target$269.00
Detailed analyst forecasts for ASND
Showing 1–18 of 18 named analysts shown · 17 active firms in the rating projection
As of Nov 19, 2026, 17 of 17 active firms rate ASND a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ASND EPS & revenue forecast
EPS · NEXT QUARTER
$1.52
Range $1.52 – $1.52 · 1 analysts · +463% YoY
Next period, 1 analysts expect Ascendis Pharma AS to earn $1.52 a share (range $1.52 – $1.52), versus $0.27 a year earlier. Full-year consensus is $12.37, growing to $10.78 the year after.
REVENUE · NEXT QUARTER
$445.9M
Range $424.0M – $477.0M · 1 analysts · +68% YoY
Revenue is expected to reach $445.9M (range $424.0M – $477.0M), +68.0% year-over-year. Full-year consensus is $1.4B, rising to $2.0B next year.
Top analysts covering Ascendis Pharma AS
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ASND.
#1
Luca Issi
RBC Capital · Rank #76
Buy
$290.00+7.3% to target
Overall win rate
49%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Buy
No targeton ASND
Overall win rate
54%
+ Follow
#3
Paul Choi
Goldman Sachs · Rank #110
Buy
$300.00+11.0% to target
Overall win rate
52%
+ Follow
#4
Joseph Schwartz
Leerink Partners · Rank #242
Buy
$305.00+12.9% to target
Overall win rate
36%
+ Follow
#5
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$335.00+24.0% to target
Overall win rate
33%
+ Follow
ASND stock forecast FAQ
What is ASND's average 12-month price target?+
The 17 active firms with a live target average $315.35 for Ascendis Pharma AS over the next 12 months, ranging from a $355.00 high to a $269.00 low, as of Nov 19, 2026.
Is ASND stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 17 active firms as of Nov 19, 2026, 17 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ASND?+
The Street-high target is $355.00 (Citigroup), and the Street-low is $269.00 (UBS). The average of all 17 active-firm targets is $315.35.
How many active Wall Street firms cover ASND?+
17 active firms have a recognized rating on Ascendis Pharma AS as of Nov 19, 2026, and 17 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ASND?+
Among analysts who currently cover ASND, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Buy with a $290.00 target.
What is Ascendis Pharma AS's projected EPS for next quarter?+
The consensus estimate is $1.52 per share (range $1.52 – $1.52) across 1 analysts. Full-year EPS is projected at $12.37, rising to $10.78 the following year.
How much revenue is Ascendis Pharma AS expected to report next quarter?+
Consensus revenue is $445.9M (range $424.0M – $477.0M). Full-year revenue is projected at $1.4B, growing to $2.0B next year.
Have analysts been upgrading or downgrading ASND lately?+
As of Nov 19, 2026, 17 of 17 active firms rate ASND a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ASND calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.